Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test could predict when breast cancer patients can safely stop treatment

NCT ID NCT06663787

First seen Jan 09, 2026 · Last updated May 22, 2026 · Updated 20 times

Summary

This study looks at using a personalized blood test (ctDNA) to detect tiny amounts of cancer DNA in 50 patients with HER2-positive metastatic breast cancer who have had a good response to anti-HER2 therapy for at least two years. The goal is to see if the test can help doctors decide whether to continue or stop maintenance treatment. This is an observational study, not a treatment trial, and aims to gather information for future treatment strategies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Aichi Cancer Center

    Nagoya, Aichi-ken, 4678601, Japan

  • Nagoya City University

    Nagoya, Aichi-ken, 4678601, Japan

  • Natera

    San Carlos, Texas, 94070, United States

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Tokyo, Tokyo, 135-8550, Japan

Conditions

Explore the condition pages connected to this study.